Zoetis Surges 0.51% on Strong Q2 Earnings and Raised Guidance Despite 451st Trading Volume Rank

Zoetis (ZTS) rose 0.51% on September 4, 2025, with a trading volume of $0.23 billion, ranking 451st in market activity. The stock’s performance was driven by strong Q2 results, including $1.76 earnings per share—$0.14 above estimates—and $2.46 billion in revenue, exceeding expectations by $50 million. The company raised its full-year 2025 guidance to $6.30–$6.40 EPS, surpassing the $6.231 consensus, and highlighted growth in its companion animal portfolio offsetting declines in Librela sales.

Analyst sentiment shifted amid the earnings beat, with William Blair upgrading its FY2025 EPS estimate to $6.34 from $6.26, while Leerink Partners and Stifel downgraded their ratings to “Market Perform” and “Hold,” respectively. Despite mixed analyst actions, Zoetis reaffirmed its market leadership in animal health, with a 5.8% EPS beat in Q2 fueling upward revisions for future periods. The stock’s rally followed improved guidance and strategic focus on pet medicine adoption, as emphasized by the CFO.

Trading data showed increased institutional activity, including PDT Partners LLC trimming its stake by 64% in Q1. However, the broader institutional ownership remains at 92.8%, reflecting confidence in Zoetis’ long-term growth potential. The company’s revised FY2025 outlook underscores strong operational execution and demand resilience in core markets.

Zoetis reported Q2 earnings of $1.76 per share, surpassing estimates by $0.14, and raised full-year 2025 guidance to $6.30–$6.40 EPS. Revenue of $2.46 billion exceeded expectations by $50 million, driven by growth in companion animal products and improved operational efficiency.